Zou Su

Dr. Zou Su


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ZKZun-Ping Ke
Zun-Ping Ke
JGJia-Ning Gu
Jia-Ning Gu
CYChen-Xi Yang
Chen-Xi Yang
XLXue-Lin Li
Xue-Lin Li
ZSZou Su
Zou Su
YYYi-Qing Yang
Yi-Qing Yang
Background/Objectives: Dilated cardiomyopathy (DCM), defined as dilation and contractile dysfunction of the left or both cardiac ventricles, remains the most common category of primary myocardial disease worldwide. It is the most prevalent cause of chronic heart failure and the most common indication for cardiac transplantation in young subjects. Accumulating evidence increasingly highlights the substantial genetic defects underlying DCM. Nevertheless, the genetic ingredients accountable for DCM in a major percentage of patients remain indefinite. Methods: A multigenerational pedigree suffering from DCM and a total of 276 healthy volunteers employed as controls were recruited from the Chinese Han-ethnicity population. A whole-exome sequencing (WES) assay followed by a Sanger sequencing analysis of the genomic DNAs from the available family members was implemented. Functional characterization of the identified genetic variant was completed by dual-luciferase analysis. Results: A new heterozygous variation in the ETS1 (erythroblast transformation-specific 1) gene, NM_005238.4:c.447T>G;p.(Tyr149*), was identified by WES and validated by Sanger sequencing analysis to co-segregate with DCM in the whole DCM family. This nonsense ETS1 variant was not found in 276 control subjects. Functional examination elucidated that Tyr149*-mutant ETS1 lost the ability to transactivate its downstream target genes CLDN5 (claudin 5) and ALK1 (activin receptor-like kinase 1), two genes crucial for cardiovascular embryonic development and postnatal structural remodeling. Conclusions: The present investigation reveals ETS1 as a new gene predisposed to human DCM and indicates ETS1 haploinsufficiency as an alternative molecular pathogenesis underlying DCM, providing a potential molecular target for genetic counseling and early diagnosis as well as personalized prophylaxis of DCM.

1 March 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
YLYan-Jie Li
Yan-Jie Li
ZSZou Su
Zou Su
YBYi-Zhe Bian
Yi-Zhe Bian
XLXing-Yuan Liu
Xing-Yuan Liu
CYChen-Xi Yang
Chen-Xi Yang
RHRi-Tai Huang
Ri-Tai Huang
Background/Objectives: Congenital bicuspid aortic valve (BAV) signifies the most frequent category of congenital cardiovascular anomaly globally, occurring in approximately 0.5–2% of the general population worldwide. BAV is a major cause of thoracic aortopathy, encompassing aortic stenosis, aortic root dilation with regurgitation, aortic dissection, and aortic aneurysms, consequently leading to substantial late-onset morbidity and mortality. Accumulating evidence convincingly demonstrates the strong genetic basis underpinning BAV, though the inheritable reasons responsible for BAV in most patients remain largely obscure. Methods: A genome-wide genotyping with 400 polymorphic genetic markers followed by linkage analysis, haplotype assay, and sequencing analysis of candidate genes was conducted in a 4-generation BAV kindred of 47 individuals. Biochemical assays were performed to evaluate the functional effect of the identified mutation on TBX20. Results: A novel BAV-causative locus was mapped to chromosome 7p14. A sequencing assay of the genes within the mapped chromosomal region (locus) unveiled that only the c.656T>G (p.Ile219Arg) variation of TBX20 was in co-segregation with BAV in the entire pedigree. The missense mutation was not uncovered in 322 healthy persons employed as control individuals. Functional deciphers revealed that the mutation significantly decreased the transcriptional activation of the representative target gene ANP and the binding ability to the ANP promoter and impaired the intranuclear distribution of TBX20. Conclusions: This investigation maps a new genetic locus (chromosome 7p14) linked to BAV and uncovers TBX20 as a novel causative gene for familial BAV, adding more insight into the mechanisms underlying BAV and providing a molecular target for the individualized management of BAV.

18 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YLYan-Jie Li
Yan-Jie Li
ZSZou Su
Zou Su
YBYi-Zhe Bian
Yi-Zhe Bian
XLXing-Yuan Liu
Xing-Yuan Liu
CYChen-Xi Yang
Chen-Xi Yang
RHRi-Tai Huang
Ri-Tai Huang
Congenital bicuspid aortic valve (BAV) signifies the most frequent category of congenital cardiovascular anomaly globally, occurring in approximately 0.5%‒2% of the general population worldwide. BAV is a major cause of thoracic aortopathy, encompassing aortic stenosis, aortic root dilation with regurgitation, aortic dissection, and aortic aneurysms, consequently leading to substantial late-onset morbidity and mortality. Accumulating evidence convincingly demonstrates the strong genetic basis underpinning BAV, though the inheritable ingredients responsible for BAV in most patients remain largely obscure. Here, by the way of genome-wide genotyping with genetic markers, genetic linkage assay, and haplotype analysis in a multigenerational BAV family, a novel BAV-causative locus was mapped to chromosome 7p14. Sequencing assay of the genes within the mapped chromosomal region (locus) unveiled that only the c.656T>G (p.Ile219Arg) variation of TBX20 was in co-segregation with BAV in the entire pedigree. The missense mutation was not uncovered in 322 healthy persons employed as control individuals. Functional deciphers revealed that the mutation significantly decreased the transcriptional activation of the representative target gene ANP and the binding ability to the ANP promoter and impaired the intranuclear distribution of TBX20. This investigation maps a new genetic locus (chromosome 7p14) linked to BAV and uncovers TBX20 as a novel causative gene for familial BAV, adding more insight into the mechanisms underlying BAV and providing a molecular target for the individualized management of BAV.

9 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ZKZun-Ping Ke
Zun-Ping Ke
JGJia-Ning Gu
Jia-Ning Gu
CYChen-Xi Yang
Chen-Xi Yang
XLXue-Lin Li
Xue-Lin Li
ZSZou Su
Zou Su
YYYi-Qing Yang
Yi-Qing Yang
Background/Objectives: Dilated cardiomyopathy (DCM), defined as dilation and contractile dysfunction of the left or both cardiac ventricles, remains the most common category of primary myocardial disease worldwide. It is the most prevalent cause of chronic heart failure and the most common indication for cardiac transplantation in young subjects. Accumulating evidence increasingly highlights the substantial genetic defects underlying DCM. Nevertheless, the genetic ingredients accountable for DCM in a larger percentage of cases remain indefinite. Methods: In the present research, a multigenerational pedigree suffering from DCM and a cohort of 276 healthy volunteers employed as control individuals were recruited from the Chinese Han-ethnicity population. A whole-exome sequencing (WES) assay followed by a Sanger sequencing analysis of the genomic DNAs from the available family members was implemented. Functional characterization of the identified genetic variant was conducted by utilizing a dual-luciferase analysis system. Results: A novel heterozygous variation in the ETS1 (erythroblast transformation-specific 1) gene, NM_005238.4:c.447T>G;p.(Tyr149*), was identified by WES and validated by Sanger sequencing analysis to co-segregate with DCM in the whole DCM family. This nonsense ETS1 variant was not found in 276 control subjects. Functional decipher elucidated that Tyr149*-mutant ETS1 failed to transactivate its representative target genes CLDN5 (claudin 5) and ALK1 (activin receptor-like kinase 1), two genes crucial for cardiovascular embryonic development and postnatal structural remodeling. Conclusions: The current investigation reveals ETS1 as a novel gene predisposed to human DCM and indicates ETS1 haploinsufficiency as an alternative molecular pathogenesis underlying DCM, providing a potential molecular target for the genetic counseling and early diagnosis as well as personalized prophylaxis of DCM.

12 September 2025 in Medicine
Verified
Journal Article
Open access
RSRui Shen
Rui Shen
YLYang Lyu
Yang Lyu
CYChenxi Yang
Chenxi Yang
ZSZou Su
Zou Su
YXYing-Jia Xu
Ying-Jia Xu
Observational evidence suggests that subjective well-being (SWB) is inversely associated with cardiovascular (CV) events, yet whether this link is causal and through which pathways remains unclear. To test this, we performed a two-sample bidirectional Mendelian randomization (MR) analysis using genetic instruments for SWB (N = 2370,390) and major adverse cardiovascular events (MACE; N = 500,348). All the data were from the largest available genome-wide association studies in populations of European descent. In univariable MR, each 1-standard-deviation increase in genetically predicted SWB reduced the odds of MACE by 39% (odds ratio = 0.61; 95% confidence interval, 0.50–0.74; P = 5.82 × 10⁻⁷). This association remained after multivariable MR adjustment for general medical conditions – Alzheimer disease, hypothyroidism, hyperthyroidism, multiple sclerosis, Addison disease, Cushing syndrome, Parkinson disease, systemic lupus erythematosus, and epilepsy – which often co-occur with mood symptoms and may also influence CV risk. Two-step MR analysis identified 3 out of 46 candidates as mediators between SWB and MACE: body mass index, diastolic blood pressure and triglycerides, accounting for 13.97% (95% confidence interval, 6.34%–21.60%), 6.05% (95% confidence interval, 0.00%–12.10%) and 10.53% (95% confidence interval, 4.45%–16.60%) of the total effect of SWB on MACE, respectively. Sensitivity analyses were directionally consistent, whereas MR-Egger did not reach statistical significance. Taken together, these results suggest that higher SWB may be associated with a lower risk of CV events, partly through metabolic and hemodynamic pathways. Targeting SWB may therefore complement conventional risk-factor management in CV prevention.